Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Terminated × Cognitive Dysfunction × Clear all

Phase

Phase NA 1 Phase 4 1 Phase 3 1 Phase 2 1

Status

Completed 7 Unknown 3 Recruiting 3 Withdrawn 1 Terminated 1 Enrolling by invitation 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 364 Carcinoma, Non-Small-Cell Lung 243 Prostatic Neoplasms 183 Neoplasms 175 Neoplasm Metastasis 167 Melanoma 142 Colorectal Neoplasms 134 Leukemia, Myeloid, Acute 131 Multiple Myeloma 129 Lung Neoplasms 113 Leukemia 113 Lymphoma 104 Pancreatic Neoplasms 99 Recurrence 95 Lymphoma, Non-Hodgkin 95 Leukemia, Lymphocytic, Chronic, B-Cell 94 Carcinoma, Renal Cell 93 Ovarian Neoplasms 91 Myelodysplastic Syndromes 82 Brain Neoplasms 81 Glioblastoma 76 Precursor Cell Lymphoblastic Leukemia-Lymphoma 75 Lymphoma, Follicular 75 Lymphoma, Large B-Cell, Diffuse 72 Carcinoma, Hepatocellular 70 Squamous Cell Carcinoma of Head and Neck 66 Head and Neck Neoplasms 66 Urinary Bladder Neoplasms 53 Stomach Neoplasms 52 Leukemia, Myelogenous, Chronic, BCR-ABL Positive 52

Interventions

Methylphenidate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02970500 2023-03-23

CogMet

CHU de Quebec-Universite Laval

Phase 2 Terminated

Breast Neoplasms, Cognitive Dysfunction

Data powered by HemOnc (CC BY 4.0) Colophon ⚡